Skip to main content
. Author manuscript; available in PMC: 2020 Nov 15.
Published in final edited form as: Clin Cancer Res. 2020 Jan 22;26(10):2290–2296. doi: 10.1158/1078-0432.CCR-19-3356

Table 3:

Best Response Summary in 32 Patients with Neuroendocrine Neoplasms

Response type All patients (n=32) N(%) High-grade (n=18) N (%) Low/Intermediate grade (n=14) N(%)
CR* 1 (3) 1 (6) 0 (0)
PR 7 (22) 7 (39) 0 (0)
SD > 6 months 2 (6) 0 (0) 2 (14)
SD ≤ 6 months 11 (34) 3 (17) 8 (57)
PD 11 (34) 7 (39) 4 (29)
CR + PR 8 (25) 8 (44) 0 (0)
CR + PR + SD > 6 months 10 (31) 8 (44) 2 (14)
*

Unconfirmed CR after confirmed PR

Abbreviations: CR = complete response; PR = partial response; SD = stable disease